Saniona Ab · OMXSTO:SANION
Saniona Ab — Investor Presentation (2024)
25 slides from Saniona Ab's investor presentation, 2024
Slide 1: Clinical-stage biopharmaceutical company focused on epilepsy; leader in ion channel drug discovery
Clinical-stage biopharmaceutical company focused on epilepsy; leader in ion channel drug discovery and development SANIONA PRESENTATION, Q1 2024
Slide 2: Disclaimer
Disclaimer This company presentation (the ”Company Presentation”), which is personal to the recipient, is issued by Saniona AB (the “Company”). The Company Presentation has been prepared for information purposes only and is not to be relied upon in substitution for the exercise of independent judgem
Slide 3: Experienced Board of Directors and Management
Experienced Board of Directors and Management Board of Directors Jörgen Drejer Anna Ljung Carl Johan Sundberg Pierandrea Muglia Chairman Board member Board member Board member FERROSAN Management Thomas Feldthus Anita Milland Janus Schreiber Larsen Karin Sandager Nielsen Palle Christophersen Co-foun
Slide 4: Saniona Investment Highlights
Saniona Investment Highlights • Expanding pipeline in collaboration with partners - Tesofensine targeting market launch in 2024 together with partner, Tesomet (phase 2b), SAN711 (phase 2a) and SAN903 (phase 1) and several pre-clinical assets available for partnering • Cutting-edge proprietary ion ch
Slide 5: Successful partnership history – platform validated by several leading pharmaceutical companies
Successful partnership history – platform validated by several leading pharmaceutical companies Partnerships and spinouts Income (SEKm) Future Upside 2023 R&D collaboration/license ~4 Milestones + royalties Joint Venture ~4 33% ownership R&D collaboration/license ~20 Milestones + royalties R&D colla
Slide 6: Expanding pipeline of new drug candidates with solid scientific rationale
Expanding pipeline of new drug candidates with solid scientific rationale Product Pre- Indication Research LOP/CS Phase 1 Phase 2a Phase 2b Phase 3 Comment Candidate clinical Potential market launch 2024 – partnership with market leader Tesofensine Obesity Medix, representing near-term revenue poten
Slide 7: Saniona poised for success in epilepsy
Saniona poised for success in epilepsy Focused epilepsy pipeline addressing indications with significant medical need Selective ion-channel modulators maximize efficacy and minimize adverse effects Precision medicines addressing underlying pathology with disease modifying potential Predictive precli
Slide 8: Epilepsy – large market driven by new products addressing significant unmet medical need
Epilepsy – large market driven by new products addressing significant unmet medical need Global Epilepsy Market • >20 approved Anti Seizure Medications (ASM) – mostly generics 50 million People affected by epilepsy worldwide2 • Top 10 branded ASM accounted for 80% of sales in 20221 >6 million people
Slide 9: Epilepsy has been subject to several recent deals
Epilepsy has been subject to several recent deals Investor Target Deal Year Transaction size Comment Worldwide rights to fenfluramine (Fintepla®) Acquisition 2022 USD 1.9 billion for the treatment of seizures associated with Dravet syndrome Worldwide rights to cannabidiol (Epidiolex®) for the treatm
Slide 10: Subtype selective GABAA PAMs: maximizing efficacy, minimizing adverse events
Subtype selective GABAA PAMs: maximizing efficacy, minimizing adverse events GABAA POSITIVE ALLOSTERIC MODULATORS (PAMs): • Highly effective anti-epileptics but dose-limited by adverse effects • Modulates all GABAA receptors (α1, α2, α3 and α5) non-selectively • GABAA α1 pharmacology drives major ad
Slide 11: Saniona GABAA PAMs: differentiated pharmacology tailored to address unmet need in specific indications
Saniona GABAA PAMs: differentiated pharmacology tailored to address unmet need in specific indications SAN711: SAN2219: GABA program: Precision medicine for absence seizures Strong seizure control devoid of Strong seizure control with additional devoid of liability for attentional GABAA α1 use limit
Slide 12: Epilepsy Pipeline
Epilepsy Pipeline Product Expansion Pre- Indication Research LOP/CS Phase 1 Phase 2 Status Candidate opportunity clinical Positive Phase 1 data reported SAN711 Generalized Absence seizures w/ target engagement imaging GABA α3 PAM idiopathic epilepsy biomarker SAN2219 On demand Refractory Focal Ready
Slide 13: Portfolio of precision medicines for epilepsy indications with significant unmet medical need
Portfolio of precision medicines for epilepsy indications with significant unmet medical need and potential to be first approved and/or first-in-class therapies Pipeline asset SAN711 SAN2219 GABA program SAN2355 Developmental epileptic Acute on demand seizure control Treatment refractory focal onset
Slide 14: Potential first-in-class precision medicine for treatment of absence seizures
Potential first-in-class precision medicine for treatment of absence seizures SAN711 • ABSENCE SEIZURES – short episodes of impairment of consciousness caused by aberrant Spike-Wave-Discharges Up to 10% Of all childhood epilepsy2 • First line therapy impairs cognition and carries risk for women of c
Slide 15: Precision medicine by selectively targeting disease pathophysiology
Precision medicine by selectively targeting disease pathophysiology SAN711 Strong effects in a highly predictable rodent model for absence seizures • Robust effects obtained in two independent studies (academia and CRO) • SAN711 precision pharmacology prevents absence seizures by abolishing SWDs in
Slide 16: Innovative trial design for Proof of Concept
Innovative trial design for Proof of Concept SAN711 Objective Endpoint with Dose Selected based on Target Engagement Biomarker • PoC– Single Country (BE) - multi-centre (Brussels, Leuven, Gent) – Double-blind, placebo controlled, parallel-group study to assess Effect on EEG and Absence Seizures usin
Slide 17: Focused profile targeting GABAA a2 and a3 receptors vs. current standard of care
Focused profile targeting GABAA a2 and a3 receptors: a clear differentiating potential vs. SAN2219 current standard of care for acute, on demand seizures control devoid of use limitations • ACUTE REPETITIVE SEIZURES (ARS) are bouts of seizures over a short period of time despite preventive antiseizu
Slide 18: Balanced pharmacology optimized for additional seizure control
Balanced pharmacology optimized for additional seizure control GABA Potential to be the first approved treatment for SWAS program • SPIKE-WAVE ACTIVATION DURING SLEEP (SWAS) – rare infant onset syndrome with no approved treatment • Results in cognitive- and developmental regression • Successful earl
Slide 19: Saniona Kv7 activators: Unique subtype selective Kv7.2-7.3 activators
Saniona Kv7 activators: Unique subtype selective Kv7.2-7.3 activators with SAN2355 potential to be devoid of dose-limiting CNS adverse effects and blue discolorations Kv7 ACTIVATORS: • Non-selective activators proven effective in treatment refractory focal onset epilepsy (Retigabine, Trobalt®/Ezogab
Slide 20: Unique selective activator of Kv7.2-7.3 subtypes
Unique selective activator of Kv7.2-7.3 subtypes SAN2355 Differentiated pharmacology with strong seizure control and superior adverse effect profile • DRUG REFRACTORY FOCAL ONSET EPILEPSY evades standard antiseizure medication • 30 % unable to achieve seizure freedom • Severely increases the disease
Slide 21: Advancing current epilepsy pipeline – potential to close valuation gap to peers
Advancing current epilepsy pipeline – potential to close valuation gap to peers Market cap (USDm)1 Comment Dopamine agonist for Parkinson’s (Phase 3) and Cerevel Therapeutics 4.049 GABA 2/3 PAM (Darigabat) for epilepsy (Phase 2) Glutamate program for ataxia and OCD (Phase 3) and Biohaven 2.149 Kv7 p
Slide 22: GABA and Kv7 ion channel compounds expected to outgrow the Epilepsy market
GABA and Kv7 ion channel compounds expected to outgrow the Epilepsy market • Saniona’s GABA-program and Kv7-program have potential to provide significant value Epilepsy market 2021 • Development of GABA and Kv7-program prioritized by Saniona 0% • Current Kv7-programs highly valued 17% Kv7 ion channe
Slide 23: Eating disorders candidates – targeting market launch and partnering
Eating disorders candidates – targeting market launch and partnering • Tesofensine – targeting market launch 2024 • Tesomet – positioned for partnering following successful phase 2a data (2019) – Q1 2023 Mexican regulatory authority expressed favorable opinion1 for treatment of obesity • Orphan desi
Slide 24: Saniona Investment Highlights
Saniona Investment Highlights • Expanding pipeline in collaboration with partners - Tesofensine targeting market launch in 2024 together with partner, Tesomet (phase 2b), SAN711 (phase 2a) and SAN903 (phase 1) and several pre-clinical assets available for partnering • Cutting-edge proprietary ion ch
Slide 25: Thank You
-if. sanlo Thank You